Papanikolaou George, Chandrinou Helen, Bouzas Evrydiki, Contopoulos-Ioannidis Despina, Kalotychou Vassiliki, Prentzas Konstantinos, Lilakos Konstantinos, Asproudis Ioannis, Palaiologou Danai, Premetis Evangelos, Papassotiriou Ioannis, Sakellaropoulos Nikos
First Department of Internal Medicine, Athens University Medical School, "Laikon" General Hospital, Athens, Greece.
Blood Cells Mol Dis. 2006 Jan-Feb;36(1):33-40. doi: 10.1016/j.bcmd.2005.10.003. Epub 2006 Jan 5.
Hereditary hyperferritinemia-cataract syndrome (HHCS) is a well-characterized autosomal dominant disease caused by mutations in the iron responsive element (IRE) of ferritin L-chain (FTL) mRNA. Mutations in the IRE result in reduced binding of the trans-acting iron regulatory proteins (IRPs) and hence in upregulation of ferritin L-chain synthesis. The disease is characterized by increased L-ferritin in serum and tissues and early onset of bilateral cataracts. Iron metabolism is normal, and there is no tissue iron overload. At least 25 nucleotide substitutions and deletions in the L-ferritin IRE have been described in families with HHCS, originating from diverse European, Australian and North American populations. We studied the molecular pathogenesis of HHCS in three unrelated kinderships of western Greek origin, with 19 affected members. We identified a relatively rare C39G mutation located in the hexanucleotide loop of L-ferritin IRE. Computational analysis of mRNA folding of mutant FTL IRE predicted that the C39 > G mutation leads to a rearrangement of base pairing in this critical region, which is likely to modify the IRP binding affinity. All subjects with HHCS were heterozygotes for the same C39G mutation. Clinical and laboratory phenotypes were described. Moreover, there was evidence of an association between this FTL IRE stem-loop mutation and very high ferritin levels. Our findings broaden the list of populations where HHCS has been described.
遗传性高铁蛋白血症-白内障综合征(HHCS)是一种特征明确的常染色体显性疾病,由铁蛋白L链(FTL)mRNA的铁反应元件(IRE)突变引起。IRE中的突变导致反式作用铁调节蛋白(IRP)的结合减少,从而导致铁蛋白L链合成上调。该疾病的特征是血清和组织中L-铁蛋白增加以及双侧白内障早发。铁代谢正常,且无组织铁过载。在来自不同欧洲、澳大利亚和北美人群的HHCS家族中,已描述了L-铁蛋白IRE中至少25种核苷酸替换和缺失。我们研究了来自希腊西部的三个无亲缘关系家族中HHCS的分子发病机制,这些家族中有19名患者。我们在L-铁蛋白IRE的六核苷酸环中鉴定出一个相对罕见的C39G突变。对突变型FTL IRE的mRNA折叠进行的计算分析预测,C39>G突变会导致该关键区域碱基配对的重排,这可能会改变IRP的结合亲和力。所有HHCS患者均为同一C39G突变的杂合子。描述了临床和实验室表型。此外,有证据表明这种FTL IRE茎环突变与非常高的铁蛋白水平之间存在关联。我们的研究结果拓宽了已描述HHCS的人群范围。